Innovative Nasal Solution Spirox specializes in developing advanced nasal implants to address nasal valve collapse, a common yet undertreated cause of nasal obstruction affecting over 20 million patients in the US. This positions the company as a key innovator in minimally invasive treatments for nasal airflow issues.

Growth through Strategic Investment With a substantial $45 million Series C funding led by KKR and recent acquisition by Entellus Medical, Spirox has demonstrated strong investor confidence and a solid financial foundation, indicating potential for expanded R&D and market reach in the medical device space.

Market Focus and Expansion Currently offering the LATERA nasal implant exclusively in the US, Spirox presents an opportunity to partner on expanding product availability internationally or developing complementary solutions to increase market penetration within the existing domestic footprint.

Relatively Small Company As a lean organization with fewer than 50 employees, Spirox offers the agility of a startup, making it responsive to market needs and open to forming strategic alliances or licensing agreements to accelerate growth and technology adoption.

Strong R&D Foundation The release of 1-year clinical data from the first-in-human study of LATERA underscores a commitment to evidence-based innovation, creating opportunities to showcase clinical efficacy and collaborate with healthcare providers and insurers to expand adoption.